Applied DNA Sciences, Inc.
APDN
$0.862
-$0.0018-0.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 34.27% | 4.28% | -72.66% | -78.91% | -83.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.27% | 4.28% | -72.66% | -78.91% | -83.07% |
| Cost of Revenue | -22.36% | -18.91% | -66.49% | -75.62% | -77.12% |
| Gross Profit | 196.02% | 210.00% | -80.68% | -83.64% | -90.28% |
| SG&A Expenses | -14.63% | -18.92% | -18.63% | -14.83% | 17.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.10% | -17.50% | -28.26% | -36.06% | -27.79% |
| Operating Income | 21.78% | 21.57% | -17.05% | -33.79% | -210.84% |
| Income Before Tax | -136.11% | 8.35% | 159.39% | -915.28% | 70.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -136.11% | 8.35% | 159.39% | -915.28% | 70.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.27% | -27.35% | 110.42% | -37.37% | 2,700.00% |
| Net Income | -138.84% | 8.23% | 160.64% | -859.90% | 71.25% |
| EBIT | 21.78% | 21.57% | -17.05% | -33.79% | -210.84% |
| EBITDA | 16.75% | 16.84% | -27.99% | -45.43% | -296.56% |
| EPS Basic | 67.82% | 93.96% | 109.75% | -682.38% | 70.94% |
| Normalized Basic EPS | 94.78% | 93.94% | 109.87% | -640.62% | 73.22% |
| EPS Diluted | 67.82% | 93.96% | 109.75% | -682.38% | 71.16% |
| Normalized Diluted EPS | 94.78% | 93.94% | 109.87% | -640.62% | 73.22% |
| Average Basic Shares Outstanding | 4,501.46% | 1,414.71% | 521.99% | 35.00% | 5.93% |
| Average Diluted Shares Outstanding | 4,501.46% | 1,414.71% | 521.99% | 35.00% | 5.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |